Since 2013, the U.S. Centers for Disease Control and Prevention has been saying that, in their conservative estimate, at least 2 million people in the U.S. are infected with an antimicrobial resistant pathogen and at least 23,000 die from it.
But those numbers likely are much higher. By mid-November, the public will know more when the agency is expected to release its second antibiotic resistance threat report. The new numbers are likely to show that antimicrobial resistance is worsening and more people are dying from resistant pathogens than previously believed. Continue reading
Since the dawn of antibiotics, there has been antibiotic resistance. Until about 20 years ago, this threat remained muted because there were plenty of new antibiotics in the pipeline to replace those that had stopped working.
Today, there are fewer than 50 antimicrobials in the pipeline, according to Pew Charitable Trusts. Resistant bacteria, meanwhile, are slowly but surely spreading across the planet. If nothing changes, British think tank the Wellcome Trust, estimates that 10 million people will die annually from a resistant microbe by 2050. Continue reading
Photo: CDC/ Melissa Dankel
Researchers are looking to old drugs, plants and viruses in a race to find new ways to kill disease-causing microbes before they become resistant to all existing pharmaceuticals, but their work will flounder if the federal government can’t figure out how to incentive companies to turn their work into commercially viable drugs. Continue reading
Since antibiotics were widely introduced in the mid 1940’s, scientists warned of microbes’ innate ability to evolve and develop resistance. People were cautioned to be judicious with antimicrobials, because overuse could breed “superbugs,” germs resistant to most or all antibiotics.
Indeed, microbes have developed resistance to virtually every new class of antibiotics introduced. Up until the 1980s, however, most pharmaceutical companies kept developing new antibiotics. When a drug developed resistance, there was a new one in the development pipeline that could take its place. Continue reading
In early October, the U.S. Food and Drug Administration approved Paratek Pharmaceuticals’ new antibiotic Nuzyra, which kills bacteria associated with skin and lung infections.
The approval was notable because there are so few new antibiotics coming onto the market, , says journalist Maryn McKenna in Wired magazine, largely because most drug companies don’t think antibiotics — which have wiped out the threat of many infectious diseases — to be worth the investment.
The problem is a unique business and policy dilemma for society. Continue reading
Looking for a local angle to cover antibiotic resistance?
Reporters can find potential stories by looking at the Centers for Disease Control and Prevention’s newly released antibiotic resistance investment map which provides details on superbug cases in states and CDC efforts to contain their spread. Continue reading